Alterations in cholesterol and ganglioside GM1 content of lipid rafts in platelets from patients with Alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 29, Issue 1, 2015, Pages 63-69

  Liu, Li ^a,b   Zhang, Ke ^a   Tan, Liang ^a   Chen, Yu Hua ^a   Cao, Yun Peng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Shenyang Fifth People's Hospital   (China)

Author keywords

Alzheimer disease; amyloid protein (Ab); lipid raft; platelet

Indexed keywords

CHOLESTEROL; GANGLIOSIDE GM1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOTTING; CHINESE; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; DIAGNOSTIC VALUE; FEMALE; HUMAN; LIPID RAFT; MALE; PRIORITY JOURNAL; THROMBOCYTE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CELL MEMBRANE; METABOLISM; MIDDLE AGED; PSYCHOLOGY;

AGED; ALZHEIMER DISEASE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS; CHOLESTEROL; FEMALE; G(M1) GANGLIOSIDE; HUMANS; MALE; MEMBRANE MICRODOMAINS; MIDDLE AGED;

EID: 84924233783     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0000000000000041     Document Type: Article

References (40)

1. Wimo A, Prince M. World Alzheimer Report 2010-The Global Economic Impact of Dementia. London: Alzheimer's Disease International; 2010.
2. Cordy JM, Hooper NM, Turner AJ. The involvement of lipid rafts in Alzheimer's disease. Mol Membr Biol. 2006;23: 111-122.
3. Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 1997;387:569-572.
4. Rushworth JV, Hooper NM. Lipid rafts: linking Alzheimer's amyloid-b production, aggregation, and toxicity at neuronal membranes. Int J Alzheimers Dis. 2011;603052:1-14.
5. Lewis V, Hooper NM. The role of lipid rafts in prion protein biology. Front Biosci. 2011;16:151-168.
6. Ohno-Iwashita Y, Shimada Y, Hayashi M, et al. Plasma membrane microdomains in aging and disease. Geriatr Gerontol Int. 2010;1:S41-S52.
7. Kojro E, Gimpl G, Lammich S, et al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the a-secretase ADAM 10. Proc Natl Acad Sci USA. 2001;98: 5815-5820.
8. Wada S, Morishima-Kawashima M, Oi Y, et al. Gammasecretase activity is present in rafts but is not cholesteroldependent. Biochemistry. 2003;42:13977-13986.
9. Riddell DR, Christie G, Hussain I, et al. Compartmentalization of b-secretase into low-buoyant density, noncaveolar lipid rafts. Curr Biol. 2001;11:1288-1293.
10. Ehehalt R, Keller P, Haass C, et al. Amyloidogenic processing of the Alzheimer b-amyloid precursor protein depends on lipid rafts. J Cell Biol. 2003;160:113-123.
11. Cordy JM, Hussain I, Dingwall C, et al. Exclusively targeting b-secretase to lipid rafts by GPI-anchor addition up regulates b-site processing of the amyloid precursor protein. Proc Natl Acad Sci USA. 2003;100:11735-11740.
12. Kakio A, Nishimoto S, Kozutsumi Y, et al. Formation of a membrane-active form of amyloid b-protein in raft-like model membranes. Biochem Biophys Res Commun. 2003;303:514-518.
13. Blennow K, Hampel H, Weiner M, et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131-144.
14. Mckhann G, Drachman D, FolsteinM, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939-944.
15. Rezai-Zadeh K, Gate D, Szekely CA, et al. Can peripheral leukocytes be used as Alzheimer's disease biomarkers? Expert Rev Neurother. 2009;9:1623-1633.
16. Borroni B, Aqosti C, Marcello E, et al. Blood cell markers in Alzheimer disease: amyloid precursor protein form ratio in platelets. Exp Gerontol. 2010;45:53-56.
17. Colciaghi F, Marcello E, Borroni B, et al. Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology. 2004;62:498-501.
18. Blank N, Gabler C, Schiller M, et al. A fast, simple and sensitive method for the detection and quantification of detergent-resistant membranes. J Immunol Methods. 2002;271: 25-35.
19. Shrimpton CN, Gousset K, Tablin F, et al. Isolation and analysis of platelet lipid rafts. Methods Mol Biol. 2004;273:213-228.
20. Tizon B, Ribe EM, Mi W, et al. Cystatin C protects neuronal cells from amyloid-b-induced toxicity. J Alzheimers Dis. 2010;19:885-894.
21. Pike LJ. Lipid rafts: bringing order to chaos. J Lipid Res. 2003;44:665-667.
22. Vetrivel KS, Thinakaran G. Membrane rafts in Alzheimer's disease beta-amyloid production. Biochim Biophys Acta. 2010;1801:860-867.
23. Schenqrund CL. Lipid rafts: keys to neurodegeneration. Brain Res Bull. 2010;82:7-17.
24. Martin V, Fabelo N, Santpere G, et al. Lipid Alterations in Lipid rafts from Alzheimer's disease human brain cortex. J Alzheimers Dis. 2010;19:489-502.
25. Simons K, Gerl MJ. Revitalizing membrane rafts: new tools and insights. Nat Rev Mol Cell Biol. 2010;11:688-699.
26. Schuck S, Honsho M, Ekroos K, et al. Resistance of cell membranes to different detergents. Proc Natl Acad Sci USA. 2003;100:5795-5800.
27. Macdonald JL, Pike LJ. A simplified method for the preparation of detergent-free lipid rafts. J Lipid Res. 2005;46: 1061-1067.
28. Molander-Melin M, Blennow K, Bogdanovic N, et al. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development: increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent resistant membrane domains. J Neurochem. 2005;92:171-182.
29. Yanagisawa K. Pathological significance of ganglioside clusters in Alzheimer's disease. J Neurochem. 2011;116:806-812.
30. Williamson R, Sutherland C. Neuronal membranes are key to the pathogenesis of Alzheimer's disease: the role of both raft and non-raft membrane domains. Curr Alzheimer Res. 2011;8:213-221.
31. Hayashi H, Kimura N, Yamaguchi H, et al. A seed for Alzheimer amyloid in the brain. J Neurosci. 2004;24: 4894-4902.
32. Peters I, Igbavloa U, Schutt T, et al. The interaction of bamyloid protein with cellular membranes stimulates its own production. Biochim Biophys Acta. 2009;1788:964-972.
33. Kakio A, Nishimoto S, Yanagisawa K, et al. Cholesteroldependent formation of GM1 ganglioside-bound amyloid bprotein, an endogenous seed for Alzheimer amyloid. J Biol Chem. 2001;276:24985-24990.
34. Yamamoto N, Igbabvoa U, Shimada Y, et al. Accelerated Ab aggregation in the presence of GM1-ganglioside-accumulated synaptosomes of aged apoE4-knock-in mouse brain. FEBS Lett. 2004;569:135-139.
35. Wang SS, Rymer DL, Good TA. Reduction in cholesterol and sialic acid content protects cells from the toxic effects of betaamyloid peptides. J Biol Chem. 2001;276:42027-42034.
36. Yuyama K, Ynangisawa K. Sphingomyelin accumulation provides a favorable milieu for GM1 ganglioside-induced assembly of amyloid b-protein. Neurosci Lett. 2010;481:168-172.
37. Matsuzaki K, Kato K, Yanagisawa K. Ab polymerization through interaction with membrane gangliosides. Biochim Biophys Acta. 2010;1801:868-877.
38. Guardia-Laguarta C, Coma M, Pera M, et al. Mild cholesterol depletion reduces amyloid-b production by impairing APP trafficking to the cell surface. J Neurochem. 2009;110:220-230.
39. Yahi N, Aulas A, Fantini J. How cholesterol constrains glycolipid conformation for optimal recognition of Alzheimer's b amyloid peptide (Abeta1-40). PLoS One. 2010;5:e9079.
40. Shneider A, Schulz-Schaeffer W, Hartmann T, et al. Cholesterol depletion reduces aggregation of amyloid-beta peptide in hippocampal neurons. Neurobiol Dis. 2006;23:573-577.